Toronto Memory Program News Today

Could a new model of testing and drugs make this brain disease as treatable as Type 2 diabetes? As researchers run tests to find out, neuroscience is divided on what to do for now

Joe Biden’s bid for re-election comes in an era of aging rock stars, deferred retirements and celebrations of late-in-life achievements.

Allegations of dementia against America’s president contenders, unfounded or accurate, should launch a necessary conversation on brain health and workplace leadership, said a Canadian advocate for older adults.

When Tyson Haller reached his 50s, he began to notice he wasn’t so sharp at remembering names. “Very mildly, I would forget (a friend’s) wife’s name, and I’d go, ‘But

The relentless pursuit of detecting Alzheimer's has posed a grueling battle for families and the medical community, but a simple eye scan may help ease that burden.

The relentless pursuit of detecting Alzheimer’s has posed a grueling battle for families and the medical community, but a simple eye scan may help ease that burden.

Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder.

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose portion of the phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2023--

– First Clinical Study of a Central Nervous System-Administered RNAi Therapeutic Showed Rapid and Robust Target Engagement with Sustained Effect Over 6 Months with a Single Dose – – ALN-APP Continues to Demonstrate an Encouraging Clinical Safety and Tolerability Profile – – Multiple-dose Portion of Study, Part B, Being Initiated in Approved Regions –